Evolutionary Genomics (FNAM) Stock Price

Evolutionary Genomics Price

NYSE·CLOSED
0.00
​
Market closed

Revenue at Evolutionary Genomics has contracted by 44.8% per year over the past 7 years to 12,500.00 USD. For Evolutionary Genomics, the net margin of -13,695.1% is down versus -519.9% a few years ago.

Evolutionary Genomics stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Evolutionary Genomics business model & stock analysis

Evolutionary Genomics, Inc. generates revenue through the identification and validation of genes impacting commercially valuable traits in crops for the agriculture industry. The company utilizes its Adapted Traits Platform (ATP) to identify genes that control important traits in plants and animals, focusing on yield increases in corn and rice, drought tolerance, sugar content in tomatoes, and pest/disease resistance in soybeans, cassava, beans, tomatoes, and cotton. The firm applies ATP in research projects for agricultural clients seeking improved crop performance. The company targets agricultural industry clients who require gene-based solutions for enhancing crop traits such as yield, drought tolerance, and pest resistance. The Adapted Traits Platform (ATP) is central to the company's product offering, enabling throughput molecular evolution analysis through non-synonymous site (Ka) and synonymous site (Ks) analysis to identify positively selected genes. This platform identifies genes that have successfully adapted to impart new or improved traits in agricultural crops. The firm's research projects include specific applications like yield increases in corn and rice, drought tolerance in crops, and pest resistance in soybeans, cassava, beans, tomatoes, and cotton. Agricultural companies and research institutions are the primary buyers of these gene identification services. Evolutionary Genomics, Inc. focuses on the agriculture industry, specifically targeting clients who need gene validation for crop improvement. The company's services are used to identify genes responsible for commercially valuable traits such as yield, drought tolerance, and pest resistance. The firm's ATP platform is applied in research projects for crops including corn, rice, soybeans, cassava, beans, tomatoes, and cotton. Agricultural clients seeking to enhance their crop traits through gene-based solutions are the key market segment for the company's offerings.

Frequently asked questions about Evolutionary Genomics

Converted at the current exchange rate, the Evolutionary Genomics share trades at 0.00 EUR (0.00 USD).

The revenue cannot currently be calculated for Evolutionary Genomics.

The profit cannot currently be calculated for Evolutionary Genomics.

The P/E ratio cannot be calculated for Evolutionary Genomics at the moment.

The P/S cannot be calculated for Evolutionary Genomics currently.

The Eulerpool Quality Score for Evolutionary Genomics is 5/10.

The ISIN of Evolutionary Genomics is US30051F1012. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Evolutionary Genomics is FNAM. The ticker symbol is used to trade Evolutionary Genomics shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website evolgen.com
Currency
USD
Initial public offering
Mar 3, 2011
ISIN
US30051F1012
Cusip
30051F101
Market capitalization
1,332.00 USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-88.94 %
Last updated Nov 16, 2026, 3:50 AM

Evolutionary Genomics Peer Group

Evolutionary Genomics Ticker

OTC · FNAM

Evolutionary Genomics FIGI

FNAM:US · BBG001KBVLT8FNAM:PQ · BBG001KBVM70FNAM:UV · BBG001KBVM98